IBM announced its intention to acquire Confluent Inc. for 11 billion USD, offering 31 USD per share in a cash transaction. Confluent is a California-based company specializing in real-time data streaming, built on the open-source Apache Kafka platform.
The transaction, which is expected to close by mid-2026 after receiving regulatory approvals and shareholder consent, will be financed in cash by IBM. This is the company’s largest acquisition since the purchase of Red Hat in 2019 and aligns with IBM’s strategy focused on the development of software and cloud services.
Through the acquisition of Confluent, IBM plans to expand its offerings with an advanced real-time data processing platform. This technology is critical for enterprises that need to manage growing volumes of data and implement artificial intelligence solutions. Integrating Confluent’s products with IBM’s automation and security tools will enable clients to make better data-driven decisions in real time.
Confluent has recently reported significant year-over-year revenue growth, exceeding market expectations, which further underscores the company’s attractiveness in the data processing technology market. Analysts indicate that the acquisition could deliver benefits to IBM as early as the first full year after the transaction closes, with a positive impact on EBITDA and free cash flow.
For the markets, this signals that IBM is actively investing in growth and strengthening its position in the cloud and artificial intelligence sectors, responding to increasing demand for advanced data processing technologies. Although IBM shares initially saw a slight decline, the transaction reflects the company’s long-term commitment to growth and innovation in the IT industry.
Chart of the day: GBPUSD (17.12.2025)
DE40: Many informations, few movements
⏫Oil rallies 2% on Supply Uncertainty
BREAKING: Ifo business expectations drop unexpectedly 📉 🇩🇪 DE40 ticks down
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.
